Kukje Pharma Co., Ltd.

KOSE:A002720 Stock Report

Market Cap: ₩98.8b

Kukje Pharma Past Earnings Performance

Past criteria checks 2/6

Kukje Pharma's earnings have been declining at an average annual rate of -13.6%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 4.4% per year. Kukje Pharma's return on equity is 4.6%, and it has net margins of 2.7%.

Key information

-13.6%

Earnings growth rate

-13.7%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate4.4%
Return on equity4.6%
Net Margin2.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality

Nov 21
Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality

Recent updates

Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality

Nov 21
Kukje Pharma's (KRX:002720) Strong Earnings Are Of Good Quality

Kukje Pharma Co., Ltd.'s (KRX:002720) 28% Price Boost Is Out Of Tune With Revenues

Aug 08
Kukje Pharma Co., Ltd.'s (KRX:002720) 28% Price Boost Is Out Of Tune With Revenues

What Kukje Pharma Co., Ltd.'s (KRX:002720) 27% Share Price Gain Is Not Telling You

Jun 24
What Kukje Pharma Co., Ltd.'s (KRX:002720) 27% Share Price Gain Is Not Telling You

Kukje Pharma Co., Ltd.'s (KRX:002720) Share Price Not Quite Adding Up

Mar 20
Kukje Pharma Co., Ltd.'s (KRX:002720) Share Price Not Quite Adding Up

Kukje Pharma's (KRX:002720) Solid Profits Have Weak Fundamentals

Mar 20
Kukje Pharma's (KRX:002720) Solid Profits Have Weak Fundamentals

If You Had Bought Kukje Pharma (KRX:002720) Stock A Year Ago, You Could Pocket A 121% Gain Today

Mar 19
If You Had Bought Kukje Pharma (KRX:002720) Stock A Year Ago, You Could Pocket A 121% Gain Today

These 4 Measures Indicate That Kukje Pharma (KRX:002720) Is Using Debt Reasonably Well

Feb 21
These 4 Measures Indicate That Kukje Pharma (KRX:002720) Is Using Debt Reasonably Well

What Type Of Shareholders Own The Most Number of Kukje Pharma Co., Ltd. (KRX:002720) Shares?

Jan 25
What Type Of Shareholders Own The Most Number of Kukje Pharma Co., Ltd. (KRX:002720) Shares?

Kukje Pharma Co., Ltd.'s (KRX:002720) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Dec 30
Kukje Pharma Co., Ltd.'s (KRX:002720) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Investors Who Bought Kukje Pharma (KRX:002720) Shares Five Years Ago Are Now Up 227%

Dec 04
Investors Who Bought Kukje Pharma (KRX:002720) Shares Five Years Ago Are Now Up 227%

Revenue & Expenses Breakdown

How Kukje Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A002720 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24150,1244,10871,0881,838
30 Jun 24142,59736369,9412,368
31 Mar 24140,499-6,49967,6832,425
31 Dec 23135,373-8,41565,4502,646
30 Sep 23131,005-9,25962,0262,614
30 Jun 23129,044-5,20957,3852,243
31 Mar 23125,7402,24454,9162,141
31 Dec 22126,5833,55754,8051,967
30 Sep 22128,5561,44656,4322,411
30 Jun 22128,22779555,9622,873
31 Mar 22125,612-26555,2242,927
31 Dec 21119,746-1,55952,2492,772
30 Sep 21115,090-1,88250,3752,491
30 Jun 21118,750-2,01951,0722,380
31 Mar 21124,741-1,84655,0442,361
31 Dec 20130,3952,20354,7523,037
30 Sep 20131,5375,34352,5943,276
30 Jun 20124,1235,50949,4563,153
31 Mar 20117,305-1,88844,5023,025
31 Dec 19111,122-4,76143,9612,604
30 Sep 19101,855-3,84843,3192,412
30 Jun 19103,493-3,42242,7152,806
31 Mar 19104,4773,23341,5673,074
31 Dec 18107,6812,19341,6113,592
30 Sep 18117,4961,09240,4844,224
30 Jun 18122,58069642,6193,620
31 Mar 18123,9671,34044,1803,366
31 Dec 17123,3101,09245,3633,291
30 Sep 17122,1382,18945,6542,442
30 Jun 17119,2131,13445,5512,230
31 Mar 17120,52985647,6442,095
31 Dec 16120,68477348,0811,331
30 Sep 16120,507-6,75649,2971,043
30 Jun 16117,332-7,30549,0401,087
31 Mar 16116,753-5,95247,924895
31 Dec 15117,637-5,94349,0431,066
30 Sep 15119,233-6,11749,7041,721
30 Jun 15123,754-4,18250,0061,786
31 Mar 15123,037-5,39948,0661,593
31 Dec 14122,426-6,93246,4471,534
30 Sep 14123,2612,59344,2161,424
30 Jun 14121,53340944,5211,155
31 Mar 14120,46290944,2911,137
31 Dec 13120,4612,12545,292817

Quality Earnings: A002720 has a large one-off loss of ₩1.8B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A002720 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A002720 has become profitable over the past 5 years, growing earnings by -13.6% per year.

Accelerating Growth: A002720 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A002720 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).

Return on Equity

High ROE: A002720's Return on Equity (4.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 09:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kukje Pharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution